| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/02/2008 | EP1905434A1 Organic compounds comprising an S1P receptor agonist and their therapeutic use |
| 04/02/2008 | EP1905431A1 Pravastatin pharmaceutical formulations and methods of their use |
| 04/02/2008 | EP1905428A1 Ibuprofen efferscent tablet with dissolution rate and process for preparation |
| 04/02/2008 | EP1905427A1 Rapidly solubilising formulation of non-steroidal anti-inflammatory drugs |
| 04/02/2008 | EP1905426A2 Anti-acid pharmaceutical composition in powder form; pharmaceutical preparation containing it and process for making it |
| 04/02/2008 | EP1905425A1 Reverse vesicle containing a hydrophobic phase |
| 04/02/2008 | EP1905424A2 Pharmaceutical composition comprising stabilized statin particles |
| 04/02/2008 | EP1904654A2 Methods of identifying and treating individuals exhibiting mutant src kinase polypeptides |
| 04/02/2008 | EP1904553A1 Method of biomolecule immobilization on polymers using click-type chemistry |
| 04/02/2008 | EP1904530A2 Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment |
| 04/02/2008 | EP1904514A2 Crystalline forms of ciclesonide |
| 04/02/2008 | EP1904513A2 Improved processes for the preparation of purified solanesol, solanesyl bromide and solanesyl acetone |
| 04/02/2008 | EP1904512A1 Purine derivatives as agonists of the adenosine a2a receptor |
| 04/02/2008 | EP1904511A2 Homogemcitabines |
| 04/02/2008 | EP1904506A1 Antiviral compounds |
| 04/02/2008 | EP1904505A1 Biologically active compounds obtainable from sorangium cellulosum |
| 04/02/2008 | EP1904504A2 Inhibitors of vegf receptor and hgf receptor signaling |
| 04/02/2008 | EP1904503A1 1h-thieno[2,3-c]-pyrazole compounds useful as kinase inhibitors |
| 04/02/2008 | EP1904502A2 Antiarrhythmic precursor compounds, methods of synthesis and methods of use |
| 04/02/2008 | EP1904501A2 Chemical compounds |
| 04/02/2008 | EP1904500A1 New derivatives of heptaazaphenalene, methods for obtaining them, and their use as protecting agents against uv radiation |
| 04/02/2008 | EP1904498A1 Fused heterocyclic derivatives and use thereof |
| 04/02/2008 | EP1904496A2 Compositions and methods pertaining to pna synthons and oligomers comprising a universal base |
| 04/02/2008 | EP1904495A2 Muscarinic receptor antagonists |
| 04/02/2008 | EP1904494A1 Imidazo[1,2-a]pyridine compounds as vegf-r2 inhibitors |
| 04/02/2008 | EP1904493A1 Tetrahydroprotoberberine compounds, the synthetic method and the use thereof |
| 04/02/2008 | EP1904491A2 Heterocycles useful as modulators of ion channels |
| 04/02/2008 | EP1904490A1 Ethanolamine salt of n- (3-methoxy-5-methylpyrazin-2yl) -2- (4- [1 , 3 , 4-0xadiaz0le-2-yl]phenyl) pyridine-3- sulphonamide |
| 04/02/2008 | EP1904488A1 Pyrazole compounds and thrombopoietin receptor activators |
| 04/02/2008 | EP1904487A2 Indole derivatives for the treatment of tuberculosis |
| 04/02/2008 | EP1904485A2 Synthesis and complete stereochemical assignment of psymberin/irciniastatin for anti-tumor use |
| 04/02/2008 | EP1904484A1 Compounds |
| 04/02/2008 | EP1904483A1 Benzimidazole derivatives as 5-ht6,5-ht24 |
| 04/02/2008 | EP1904482A2 Indolylmaleimide derivatives |
| 04/02/2008 | EP1904480A2 Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts |
| 04/02/2008 | EP1904479A2 Novel 2,4-dianilinopyrimidine derivatives, the preparation thereof, their use as medicaments, pharmaceutical compositions and, in particular, as ikk inhibitors |
| 04/02/2008 | EP1904478A1 Acid addition salts of n-ethyl-n'-[2-methoxy-4-(5-methyl-4-{[(1s)-1-pyridin-3-ylbutyl]amino}pyrimidin- 2-yl)phenyl]urea and uses thereof |
| 04/02/2008 | EP1904477A1 Indol-3-carbonyl-spiro-piperidine derivatives as v1a receptor antagonists |
| 04/02/2008 | EP1904476A1 Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, and their use as pharmaceuticals |
| 04/02/2008 | EP1904474A1 New pyridine analogues |
| 04/02/2008 | EP1904471A1 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents |
| 04/02/2008 | EP1904467A1 Urea glucokinase activators |
| 04/02/2008 | EP1904466A1 Dicycloalkyl urea glucokinase activators |
| 04/02/2008 | EP1904461A2 Cyclic anilinopyridinotriazines as gsk-3 inhibitors |
| 04/02/2008 | EP1904459A1 New crystal forms of 4-[6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid(4-isopropoxyphenyl)-amide |
| 04/02/2008 | EP1904457A2 Compositions and methods for inhibition of the jak pathway |
| 04/02/2008 | EP1904455A2 Pyridazine derivatives |
| 04/02/2008 | EP1904454A2 Process for the production of intermadiates for the preparation of tricyclic benzimidazoles |
| 04/02/2008 | EP1904451A1 Aryl-alkylamines and heteroaryl-alkylamines as protein kinase inhibitors |
| 04/02/2008 | EP1904449A2 Inhibitors of checkpoint kinases |
| 04/02/2008 | EP1904447A1 Piperidine carboxamide derivate suitable as tachykinin receptor antagonist |
| 04/02/2008 | EP1904446A2 Azabicyclo derivatives as muscarinic receptor antagonists |
| 04/02/2008 | EP1904444A2 Fluvastatin sodium novel forms and preparation therof |
| 04/02/2008 | EP1904442A1 Histamine h3 receptor agents, preparation and therapeutic uses |
| 04/02/2008 | EP1904440A1 Sulindac derivatives for treatment of cancer |
| 04/02/2008 | EP1904438A1 Dicycloalkylcarbamoyl ureas as glucokinase activators |
| 04/02/2008 | EP1904436A1 Modified poly(propylene-imine) dendrimers and their use as transfection agents for anionic bioactive factors |
| 04/02/2008 | EP1904434A2 Highly selective serotonin and norepinephrine dual reuptake inhibitor and use thereof |
| 04/02/2008 | EP1904432A2 Oligomers of straight-chain and unbranched fatty acids, and medicaments containing the same |
| 04/02/2008 | EP1904219A1 Method of particle formation |
| 04/02/2008 | EP1904183A2 Imaging and therapeutic method using monocytes |
| 04/02/2008 | EP1904182A2 Method for the treatment of drug abuse with flibanserin |
| 04/02/2008 | EP1904181A2 Jnk inhibitors for the treatment of endometreosis |
| 04/02/2008 | EP1904180A2 Pharmaceutical dosage form containing an active principle combination of nifedipine and/or nisoldipine and of an angiotensin ii antagonist |
| 04/02/2008 | EP1904111A2 Compositions and methods for decreasing microrna expression for the treatment of neoplasia |
| 04/02/2008 | EP1904108A2 Formulation and method for administration of ophthalmologically active agents |
| 04/02/2008 | EP1904107A2 Use of inhibitors of histone deacetylases in combination with nsaid for the therapy of cancer and/or inflammatory diseases |
| 04/02/2008 | EP1904100A1 New combination of anti-madcam antibody and antifibrotic caspase inhibitor to treat liver fibrosis |
| 04/02/2008 | EP1904083A2 Synapse-specific proteins in glomeruli |
| 04/02/2008 | EP1904077A1 Method for modulating responsiveness to steroids |
| 04/02/2008 | EP1904071A2 Compositions of antiviral compound |
| 04/02/2008 | EP1904070A1 Dietary supplement for enhancing skeletal muscle mass, decreasing muscle protein degradation, downregulation of muscle catabolism pathways, and decreasing catabolism of muscle cells |
| 04/02/2008 | EP1904069A2 Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
| 04/02/2008 | EP1904068A1 Synergistic combination for the treatment of pain (cannabioid receptor agonist and opiod receptor agonist) |
| 04/02/2008 | EP1904067A2 Pharmaceutical formulation of carboxamide hiv integrase inhibitors containing a release rate controlling composition |
| 04/02/2008 | EP1904066A2 Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders |
| 04/02/2008 | EP1904065A2 Use of dual c-kit/fgfr3 inhibitors for treating multiple myeloma |
| 04/02/2008 | EP1904064A2 Omeprazole form b |
| 04/02/2008 | EP1904063A1 Thiazole derivatives for the treatment of dyskinesias caused by a chemical treatment |
| 04/02/2008 | EP1904062A1 Thiazole derivatives for the treatment of restless legs syndrome |
| 04/02/2008 | EP1904060A1 Use of phthalocyanine derivates for the non-photodynamic treatment of diseases |
| 04/02/2008 | EP1904059A2 Method for treating nervous system disorders and conditions |
| 04/02/2008 | EP1904058A2 Combination of a dpp-iv inhibitor and a cannabinoid cb1 receptor antagonist |
| 04/02/2008 | EP1904057A2 Methods of treatment using hydroquinone ansamycins |
| 04/02/2008 | EP1904056A2 Enhanced ocular neuroprotection/neurostimulation |
| 04/02/2008 | EP1904055A1 Composition for inhibiting acyl-coa:cholesterol acyltransferase |
| 04/02/2008 | EP1904054A1 Pharmaceutical composition comprising an extract of pseudolysimachion longifolium and the catalpol derivatives isolated therefrom having antiinflammatory, antiallergic and antiasthmatic activity |
| 04/02/2008 | EP1904053A1 Isoflavone nanoparticles and use thereof |
| 04/02/2008 | EP1904052A1 Liquid pharmaceutical formulations of docetaxel |
| 04/02/2008 | EP1904051A1 Bicalutamide adsorbates, process for preparing same, and pharmaceutical compositions thereof |
| 04/02/2008 | EP1904050A2 Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to reduce cardiomyopathy |
| 04/02/2008 | EP1904049A2 Polyunsaturated fatty acids for treatment of dementia and pre-dementia-related conditions |
| 04/02/2008 | EP1904048A1 Glepp-1 inhibitors in the treatment of autoimmune and/or inflammatory disorders |
| 04/02/2008 | EP1904047A2 Apoptosis promoters |
| 04/02/2008 | EP1904046A2 Combinations of eszopiclone and o-desmethylvenlafaxine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders |
| 04/02/2008 | EP1904045A1 Use of 4-(3,4-dichloro-phenyl)-1,2,3,4-tetrahydro-naphtalen-1-ylamine for treating cancer |
| 04/02/2008 | EP1904044A1 Use of a combination comprising l-carnitine or alkanoyl l-carnitine, lipid solubl benzoquinone and omega-3-polyunsaturated fatty acid for the preparation of a dietary supplement or medicament for the treatment of corneal diseases |
| 04/02/2008 | EP1904043A2 Methods and compositions for treating ophthalmic conditions via serum retinol, serum retinol binding protein (rbp), and/or serum retinol-rbp modulation |
| 04/02/2008 | EP1904042A2 Solubilsation products of an active ingredient extract |
| 04/02/2008 | EP1904040A2 Highly bioavailable oral delayed release dosage forms of o-desmethylvenlafaxine succinate |